Wird geladen...
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial
IMPORTANCE: The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is unknown. OBJECTIVE: To confirm the safety and efficacy of bimagrumab plus the new standard of care on skeletal muscle mass, strength,...
Gespeichert in:
| Veröffentlicht in: | JAMA Netw Open |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Medical Association
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7573681/ https://ncbi.nlm.nih.gov/pubmed/33074327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.20836 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|